Recent advances in c-Met-based dual inhibitors in the treatment of cancers
F Jin, Y Lin, W Yuan, S Wu, M Yang, S Ding… - European Journal of …, 2024 - Elsevier
The cellular-mesenchymal epithelial transition factor (c-Met) is a receptor tyrosine kinase
(RTK) located on the 7q31 locus encoding the Met proto-oncogene and plays a critical role …
(RTK) located on the 7q31 locus encoding the Met proto-oncogene and plays a critical role …
[HTML][HTML] (−)-Oleocanthal as a dual c-MET-COX2 inhibitor for the control of lung cancer
Lung cancer (LC) represents the topmost mortality-causing cancer in the US LC patients
have overall poor survival rate with limited available treatment options. Dysregulation of the …
have overall poor survival rate with limited available treatment options. Dysregulation of the …
[HTML][HTML] Syngeneic tobacco carcinogen–induced mouse lung adenocarcinoma model exhibits PD-L1 expression and high tumor mutational burden
Human lung adenocarcinoma (LUAD) in current or former smokers exhibits a high tumor
mutational burden (TMB) and distinct mutational signatures. Syngeneic mouse models of …
mutational burden (TMB) and distinct mutational signatures. Syngeneic mouse models of …
Synthesis and biological evaluation of benzamide‐chalcone hybrids as potential c‐Met kinase and COX‐2 inhibitors
H Bhojwani, K Begwani, V Bhor, P Bedi… - Archiv der …, 2023 - Wiley Online Library
Abstract c‐Met kinase and cyclooxygenase 2 (COX‐2) enzymes are two significant targets in
tumor progression. Chalcone and benzamide moieties were combined using molecular …
tumor progression. Chalcone and benzamide moieties were combined using molecular …
Hepatic radiofrequency ablation: markedly reduced systemic effects by modulating periablational inflammation via cyclooxygenase-2 inhibition
G Kumar, SN Goldberg, Y Wang, E Velez… - European …, 2017 - Springer
Objectives To determine whether celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, can
potentiate hepatic radiofrequency ablation (RFA)-induced local cellular infiltration and …
potentiate hepatic radiofrequency ablation (RFA)-induced local cellular infiltration and …
Madecassoside suppresses proliferation and invasiveness of HGF-induced human hepatocellular carcinoma cells via PKC-cMET-ERK1/2-COX-2-PGE2 pathway
Z Li, K You, J Li, Y Wang, H Xu, B Gao… - International …, 2016 - Elsevier
Recent studies showed that Madecassoside (MAD), a pentacyclic triterpene isolated from
Centella asitica (L.), was used as a therapeutic agent in wound healing and also as an anti …
Centella asitica (L.), was used as a therapeutic agent in wound healing and also as an anti …
MiR-204 suppresses the progression of acute myeloid leukemia through HGF/c-Met pathway
D Nie, P Ma, Y Chen, H Zhao, L Liu, D Xin, W Cao… - …, 2021 - Taylor & Francis
Acute myeloid leukemia (AML) was confirmed to be associated with hematopoietic
insufficiency, as well as abnormal proliferation, differentiation or survival of myeloid …
insufficiency, as well as abnormal proliferation, differentiation or survival of myeloid …
Avaliação do potencial antiproliferativo do Dendrímero de Poliglicerol associado ao celecoxibe em linhagens celulares de carcinoma epidermoide de cabeça e …
RM Moura - 2014 - teses.usp.br
Diversos mecanismos celulares estão associados à patogênese do Carcinoma
Epidermoide de Cabeça e Pescoço (CECP). Algumas dessas alterações envolvem …
Epidermoide de Cabeça e Pescoço (CECP). Algumas dessas alterações envolvem …
[PDF][PDF] for the Control of Lung Cancer
AB Siddique, PCSR Kilgore, A Tajmim, SS Singh… - researchgate.net
Lung cancer (LC) represents the topmost mortality-causing cancer in the US LC patients
have overall poor survival rate with limited available treatment options. Dysregulation of the …
have overall poor survival rate with limited available treatment options. Dysregulation of the …
TWIST1 Suppresses Apoptosis and Mediates Therapeutic Resistance in Non-small Cell Lung Cancer
ZA Yochum - 2018 - search.proquest.com
Patients with non-small cell lung cancer (NSCLC) are classified into molecular subgroups
based on the presence of oncogenic drivers. Patients with targetable oncogenic drivers …
based on the presence of oncogenic drivers. Patients with targetable oncogenic drivers …